Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The XIAP mRNA 3' untranslated region (3'UTR) is a critical regulatory segment of the messenger RNA encoding the X-linked inhibitor of apoptosis protein (XIAP), also known as BIRC4 (UniProt P98170). XIAP is a potent member of the inhibitor of apoptosis (IAP) family that directly binds and inhibits caspases 3, 7, and 9, thereby blocking the execution of programmed cell death (PubMed 16418198). The 3'UTR serves as a platform for post-transcriptional regulation, containing numerous binding sites for microRNAs (miRNAs) such as miR-24 and miR-7, which control the stability and translation efficiency of the XIAP transcript (PubMed 20603077, PubMed 23812434). In many cancers, XIAP is overexpressed, contributing to tumor cell survival, poor prognosis, and resistance to chemotherapy or radiation (PubMed 19103603). Therapeutic strategies targeting the XIAP mRNA, including the 3'UTR, utilize antisense oligonucleotides (ASOs) or miRNA mimics to promote mRNA degradation or inhibit translation. By reducing XIAP protein levels, these interventions lower the threshold for apoptosis and sensitize malignant cells to pro-apoptotic stimuli. Clinical candidates like AEG35156 have been developed to target the XIAP mRNA transcript to induce apoptosis in refractory tumors, while experimental miRNA-based therapies specifically focus on the 3'UTR regulatory sites (PubMed 19103603, PubMed 20603077).
Downregulation of XIAP protein expression through antisense-mediated mRNA degradation or translational repression by targeting regulatory sequences within the mRNA transcript, particularly the 3' untranslated region.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on X-linked inhibitor of apoptosis protein messenger RNA 3' untranslated region (XIAP mRNA 3'UTR).